Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00857896 · ClinicalTrials.gov registry record · Phase 2
Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT00857896 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 21 participants.
The verdict
NCT00857896, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the pharmacokinetics, safety, and tolerability of fesoterodine following administration to pediatric patients, aged 8-17 years, with overactive bladder.
Interventions
- DRUG Fesoterodine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2009-03 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00857896
The ClinicalTrials.gov registry entry for NCT00857896 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fesoterodine is the first listed.
NCT00857896 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00857896 about?
NCT00857896 is a clinical study titled "Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years". The purpose of the study is to evaluate the pharmacokinetics, safety, and tolerability of fesoterodine following administration to pediatric patients, aged 8-17 years, with overactive bladder.
What is the current status of trial NCT00857896?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2009-03. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00857896?
The interventions under investigation include: Fesoterodine (DRUG).
Who is sponsoring clinical trial NCT00857896?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.